Online inquiry

IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ6120MR)

This product GTTS-WQ6120MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Anemia research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens; Humanized
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, COR-001(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ6120MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ7456MR IVTScrip™ mRNA-Anti-TNFRSF4, GBR-830(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA GBR-830
GTTS-WQ3192MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ1189MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABP 980
GTTS-WQ9648MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ13435MR IVTScrip™ mRNA-Anti-TNFRSF10B, PRO95780(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA PRO95780
GTTS-WQ2518MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA AMG 334
GTTS-WQ2779MR IVTScrip™ mRNA-Anti-IL1RL1, AMG-282(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG-282
GTTS-WQ12921MR IVTScrip™ mRNA-Anti-FZD10, OTSA101-DTPA(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA OTSA101-DTPA
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW